Naringenin reduces lung metastasis in a breast cancer resection model

Protein and Cell

Volumn 2, Issue 6, 2011, Pages 507-516

  Qin, Lei ^a,b   Jin, Lingtao ^a   Lu, Linlin ^a   Lu, Xiaoyan ^c   Zhang, Chunling ^a   Zhang, Fayun ^a   Liang, Wei ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

breast cancer; immunosuppression; metastasis; naringenin; surgery; Tregs

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; NARINGENIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; IMMUNOREGULATION; IN VITRO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

CITRUS; MUS; VITACEAE;

EID: 80053082680     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-011-1056-8     Document Type: Article

References (42)

1. Ben-Eliyahu, S. (2003). The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 17, S27-S36.
2. Beyer, M., and Schultze, J. L. (2006). Regulatory T cells in cancer. Blood 108, 804-811.
3. Bindea, G., Mlecnik, B., Fridman, W. H., Pages, F., and Galon, J. (2010). Natural immunity to cancer in humans. Curr Opin Immunol 22, 215-222.
4. Boomsma, M. F., Garssen, B., Slot, E., Berbee, M., Berkhof, J., Meezenbroek Ede, J., Slieker, W., Visser, A., Meijer, S., and Beelen, R. H. (2010). Breast cancer surgery-induced immunomodulation. J Surg Oncol 102, 640-648.
5. Brandacher, G., Winkler, C., Schroecksnadel, K., Margreiter, R., and Fuchs, D. (2006). Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7, 599-612.
6. Brune, I. B., Wilke, W., Hensler, T., Holzmann, B., and Siewert, J. R. (1999). Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 177, 55-60.
7. Chen, L., Huang, T. G., Meseck, M., Mandeli, J., Fallon, J., and Woo, S. L. (2007). Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 15, 2194-2202.
8. Chen, W. J., and Konkel, J. E. (2010). TGF-beta and 'Adaptive' Foxp3(+) Regulatory T cells. J Mol Cell Biol 2, 30-36.
9. Chiang, J. Y., Jang, I. K., Hodes, R., and Gu, H. (2007). Ablation of Cblb provides protection against transplanted and spontaneous tumors. J Clin Invest 117, 1029-1036.
10. Coffelt, S. B., Hughes, R., and Lewis, C. E. (2009). Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796, 11-18.
11. Coughlin, S. S., and Ekwueme, D. U. (2009). Breast cancer as a global health concern. Cancer Epidemiol 33, 315-318.
12. Du, G., Jin, L., Han, X., Song, Z., Zhang, H., and Liang, W. (2009). Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis. Cancer Res 69, 3205-3212.
13. duPre, S. A., Redelman, D., and Hunter, K. W. Jr. (2008). Microenvironment of the murine mammary carcinoma 4T1: endogenous IFNgamma affects tumor phenotype, growth, and metastasis. Exp Mol Pathol 85, 174-188.
14. Faist, E., Kupper, T. S., Baker, C. C., Chaudry, I. H., Dwyer, J., and Baue, A. E. (1986). Depression of Cellular-Immunity after Major Injury - Its Association with Posttraumatic Complications and Its Reversal with Immunomodulation. Arch Surg-Chicago 121, 1000-1005.
15. Fang, F., Tang, Y., Gao, Z., and Xu, Q. (2010). A novel regulatory mechanism of naringenin through inhibition of T lymphocyte function in contact hypersensitivity suppression. Biochem Biophys Res Commun 397, 163-169.
16. Gabrilovich, D. I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174.
17. Hogan, B. V., Peter, M. B., Shenoy, H. G., Horgan, K., and Hughes, T. A. (2011). Surgery induced immunosuppression. Surg-J R Coll Surg E 9, 38-43.
18. James, M. A., Lu, Y., Liu, Y., Vikis, H. G., and You, M. (2009). RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res 69, 2108-2116.
19. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
20. Kanno, S., Tomizawa, A., Hiura, T., Osanai, Y., Shouji, A., Ujibe, M., Ohtake, T., Kimura, K., and Ishikawa, M. (2005). Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 28, 527-530.
21. Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., and Sakaguchi, S. (2005). Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells. J Exp Med 202, 885-891.
22. Kong, L. Y., Wei, J., Sharma, A. K., Barr, J., Abou-Ghazal, M. K., Fokt, I., Weinberg, J., Rao, G., Grimm, E., Priebe, W., et al. (2009). A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58, 1023-1032.
23. Le Marchand, L., Murphy, S. P., Hankin, J. H., Wilkens, L. R., and Kolonel, L. N. (2000). Intake of flavonoids and lung cancer. J Natl Cancer Inst 92, 154-160.
24. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169, 2756-2761.
25. Lohr, F., Hu, K., Haroon, Z., Samulski, T. V., Huang, Q., Beaty, J., Dewhirst, M. W., and Li, C. Y. (2000). Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2, 195-203.
26. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008). Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222, 162-179.
27. Markiewicz, D. A., Schultz, D. J., Haas, J. A., Harris, E. E., Fox, K. R., Glick, J. H., and Solin, L. J. (1996). The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 35, 661-668.
28. McCahill, L. E., Privette, A., James, T., Sheehey-Jones, J., Ratliff, J., Majercik, D., Krag, D. N., Stanley, M., and Harlow, S. (2009). Quality measures for breast cancer surgery: initial validation of feasibility and assessment of variation among surgeons. Arch Surg 144, 455-462; discussion 462-463.
29. Ogawa, K., Hirai, M., Katsube, T., Murayama, H., Hamaguchi, K., Shimakawa, T., Naritake, Y., Hosokawa, T., and Kajiwara, T. (2000). Suppression of cellular immunity by surgical stress. Surgery 127, 329-336.
30. Ortiz-Andrade, R. R., Sanchez-Salgado, J. C., Navarrete-Vazquez, G., Webster, S. P., Binnie, M., Garcia-Jimenez, S., Leon-Rivera, I., Cigarroa-Vazquez, P., Villalobos-Molina, R., and Estrada-Soto, S. (2008). Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation. Diabetes Obes Metab 10, 1097-1104.
31. Page, G. G., and Ben-Eliyahu, S. (1997). Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Res Treat 45, 159-167.
32. Pulaski, B. A., and Ostrand-Rosenberg, S. (2001). Mouse 4T1 breast tumor model. Curr Protoc Immunol Chapter 20, Unit 20. 2.
33. Pulaski, B. A., Terman, D. S., Khan, S., Muller, E., and Ostrand-Rosenberg, S. (2000). Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60, 2710-2715.
34. Rosenberg, S. A. (2001). Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
35. Salo, M. (1992). Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 36, 201-220.
36. Shafir, M., Bekesi, J. G., Papatestas, A., Slater, G., and Aufses, A. H. (1980). Preoperative and Postoperative Immunological Evaluation of Patients with Colorectal-Cancer. Cancer 46, 700-705.
37. Shenkier, T., Weir, L., Levine, M., Olivotto, I., Whelan, T., and Reyno, L. (2004). Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 170, 983-994.
38. So, F. V., Guthrie, N., Chambers, A. F., Moussa, M., and Carroll, K. K. (1996). Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26, 167-181.
39. Townsend, S. E., and Allison, J. P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259, 368-370.
40. van der Bij, G. J., Oosterling, S. J., Bogels, M., Bhoelan, F., Fluitsma, D. M., Beelen, R. H., Meijer, S., and van Egmond, M. (2008). Blocking alpha2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth. Hepatology 47, 532-543.
41. Whiteside, T. L. (2006). Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16, 3-15.
42. Yang, Y., Xu, Y., Xia, T., Chen, F., Zhang, C., Liang, W., Lai, L., and Fang, X. (2011). A single-molecule study of the inhibition effect of Naringenin on transforming growth factor-beta ligand-receptor binding. Chem Commun (Camb) 47, 5440-5442.